3 results
DEF 14A
APGE
Apogee Therapeutics Inc.
24 Apr 24
Definitive proxy
4:15pm
The following table presents all of the compensation awarded to, earned by, or paid to our non-employee directors during the year ended December 31, 2023. We have reimbursed and will continue to reimburse all of our non-employee directors for their reasonable out-of-pocket expenses incurred in attending board of directors and committee meetings. Dr. Henderson, our CEO, does not receive any additional compensation for his service on the Board. The compensation received by Dr. Henderson for his service as our CEO is presented in the 2023 Summary Compensation Table below.
NAME | | | OPTION AWARDS ($)(1)(2) | | | STOCK AWARDS ($)(3) | | | FEES EARNED OR PAID IN CASH ($) | | | TOTAL ($) | | ||||||||||||
Peter Harwin | | | | $ | 642,823 | | | | | | — | | | | | $ | 25,750 | | | | | $ | 668,573 | | |
Jennifer Fox | | | | | — | | | | | $ | 381,323 | | | | | $ | 33,250 | | | | | $ | 414,573 | | |
Andrew Gottesdiener, M.D. | | | | $ | 642,823 | | | | | | — | | | | | $ | 23,750 | | | | | $ | 666,573 | | |
William (BJ) Jones, Jr. | | | | | — | | | | | $ | 381,323 | | | | | $ | 30,333 | | | | | $ | 411,656 | | |
Tomas Kiselak | | | | $ | 642,823 | | | | | | — | | | | | $ | 20,000 | | | | | $ | 662,823 | | |
Mark McKenna | | | | $ | 940,000 | | | | | | — | | | | | $ | 32,870 | | | | | $ | 972,870 | | |
Nimish Shah | | | | $ | 642,823 | | | | | | — | | | | | $ | 22,000 | | | | | $ | 664,823 | | |
10-K
2023 FY
APGE
Apogee Therapeutics Inc.
5 Mar 24
Annual report
6:15am
| | | | | | |
| DECEMBER 31, | DECEMBER 31, | ||||
| | 2023 | | 2022 | ||
Accrued external research and development expenses | | $ | 6,685 | | $ | 8,847 |
Accrued manufacturing expenses | | | 9,219 | | | — |
Accrued other | | 1,243 | | 200 | ||
Accrued employee compensation | | 167 | | 515 | ||
Total | | $ | 17,314 | | $ | 9,562 |
- Prev
- 1
- Next